Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

CALFACTANT
Trade name: Infasurf (Forest)
Indications: Prevention of respiratory distress syndrome
Category: Pulmonary surfactant
Half-life: N/A
Skin
Cyanosis 65%
CANDESARTAN
Reactions
Trade names: Amias; Atacand (AstraZeneca)
Indications: Hypertension
Category: Angiotensin II receptor antagonist
Half-life: 9 hours
Reactions
Skin
Angioedema
(2003): Hille K+, Am J Ophthalmol 135(2), 224
(2002): Lo KS, Pharmacotherapy 22(9), 1176
Diaphoresis (>0.5%)
Edema
Erythema multiforme
(2004): Ejaz AA+, South Med J 97(6), 614
Exanthems (1%)
Perleche
(2004): Chen C+, Nephrologie 25(3), 97
Psoriasis
(2003): Kawamura A+, Eur J Dermatol 13(4), 406
Rash (sic) (>0.5%)
(2004): Morton A+, BMJ 328(7430), 25
Mucosal
Aphthous stomatitis
(2004): Chen C+, Nephrologie 25(3), 97
Burning mouth syndrome
(2004): Chen C+, Nephrologie 25(3), 97
Stomatitis
(2004): Chen C+, Nephrologie 25(3), 97
Eyes
Glaucoma
(2003): Hille K+, Am J Ophthalmol 135(2), 224
Other
Abdominal pain
(2003): Basile G+, J Clin Gastroenterol 36(3), 273
Cough
(2002): Cuspidi C+, JHypertens20(11), 2293
Myalgia/Myositis/Myopathy/Myotoxicity (>0.5%)
Upper respiratory infection
(2004): Gleiter CH+, Cardiovasc Drug Rev 22(4), 263
CAPECITABINE
Trade name: Xeloda (Roche)
Indications: Metastatic breast cancer
Category: Antimetabolite; Antineoplastic
Half-life: 0.5–1 hour
Reactions
CAPECITABINE 85
Skin
Acral erythema
Dermatitis (37%)
(2003): Wagstaff AJ+, Drugs 63(2), 217 (25%)
(1999): Dooley M+, Drugs 58, 69
Diaphoresis (0.2%)
Edema (9%)
(1996): Bajetta E+, Tumori 82, 450
Erythema
Exfoliative dermatitis (31–37%)
Hand–foot syndrome (7–58%)
(2006): Blum JL+, J Clin Oncol 24(27), 4384 (with paclitaxel)
(2006): Crane CH+, J Clin Oncol 24(7), 1145
(2006): Gressett SM+, J Oncol Pharm Pract 12(3), 131
(2006): Kara IO+, Breast 15(3), 414 (with docetaxel)
(2006): Lin EH+, Am J Clin Oncol 29(3), 232
(2006): Saif MW+, Clin Colorectal Cancer 6(3), 219
(2006): Sharma R+, Br J Cancer 94(7), 964 (22%)
(2006): Wolf JK+, Gynecol Oncol 102(3), 468
(2006): Yamaguchi K+, Gan To Kagaku Ryoho 33(7), 891 (13%)
(2006): Yerushalmi R+, JSurgOncol93(7), 529 (2%)
(2005): Levy C+, Cancer Treat Rev 31 Suppl 4, S17
(2005): Ramanathan RK+, Cancer Chemother Pharmacol
55(4), 354
(2005): Rini BI+, Cancer 103(3), 553
(2005): Walko CM+, Clin Ther 27(1), 23
(2005): Wilkes GM+, Clin J Oncol Nurs 9(1), 103
(2004): Guo L+, Zhonghua Zhong Liu Za Zhi 26(4), 250
(2004): Heo YS+, J Clin Pharmacol 2004 Oct 44(10), 1166
(2004): Hofheinz RD+, Br J Cancer 91(5), 834 (3%)
(2004): Hong YS+, Ann Oncol 15(9), 1344 (9%)
(2004): Lassere Y+, Eur J Oncol Nurs 8 Suppl 1, S31
(2004): Lebowitz PF+, Clin Cancer Res 10(20), 6764
(2004): Lee JJ+, Jpn J Clin Oncol 34(7), 400 (35%)
(2004): Lokich J, Cancer Invest 22(5), 713 (8%)
(2004): Mackey JR+, Clin Breast Cancer 5(4), 287 (30%)
(2004): Marse H+, Eur J Oncol Nurs 8 Suppl, S16
(2004): Morant R+, Br J Cancer 90(7), 1312
(2004): Narasimhan P+, Cutis 73(2), 101 (3 cases)
(2004): Park SH+, Oncology 66(5), 353
(2004): Park YH+, Br J Cancer 90(7), 1329 (50%)
(2004): Pierga JY+, Breast Cancer Res Treat 88(2), 117
(2004): Rao S+, Br J Cancer 91(5), 839 (19.7%) (with
mitomycin)
(2004): Sakamoto J+, Anticancer Drugs 15(2), 137 (62%)
(2004): Scheithauer W+, Oncology (Williston Park) 18(9), 1161
(2004): Sternberg CN+, Eur J Oncol Nurs 8 Suppl, S4
(2003): Chua DT+, Oral Oncol 39(4), 361 (58.8%)
(2003): Gerbrecht BM, Cancer Nurs 26(2), 161
(2003): Han JY+, Cancer 98(9), 1918 (33%) (with docetaxel)
(2003): Jones KL+, Pharmacotherapy 23(8), 1076
(2003): Kalbakis K+, Int J Radiat Oncol Biol Phys 56(5), 1284 (1
case)
(2003): Makhnova EV+, Vopr Onkol 49(2), 193
(2003): Risum S+, Ugeskr Laeger 165(33), 3161
(2003): Scheithauer W+, Ann Oncol 14(12), 1735
(2003): Vasey PA+, Br J Cancer 89(10), 1843
(2003): Wagstaff AJ+, Drugs 63(2), 217 (25%)
(2002): Abushullaih S+, Cancer Invest 20(1), 3 (68.3%)